The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer

Treatment with the Toll-like receptor 7 (TLR7) agonist, resiquimod (R848), is effective in various types of cancer, such as breast, pancreatic and colorectal cancer. The reported antitumor effect of R848 in lung cancer is considered to be achieved by targeting macrophages. In the present study, it w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jianchun, Xu, Yu, Wang, Guansong, Mei, Tonghua, Yang, Hao, Liu, Yuliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162053/
https://www.ncbi.nlm.nih.gov/pubmed/35552764
http://dx.doi.org/10.3892/ijo.2022.5371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162053/
https://www.ncbi.nlm.nih.gov/pubmed/35552764
http://dx.doi.org/10.3892/ijo.2022.5371

Ejemplares similares